Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

NCT02499835 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Hormone-Resistant Prostate Cancer
Metastatic Malignant Neoplasm in the Bone
Metastatic Malignant Neoplasm in the Soft Tissues
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: pTVG-HP Plasmid DNA Vaccine

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]
[object Object]